Press Room

    Back

    Press Release - November 09, 2018

    Sernova Retains FronTier Flex for Canadian Investor Relations and Marketing


    Source: Sernova Corp November 9, 2018 6:00 a.m. EST

    LONDON, ONTARIO – November 9, 2018– Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, announces that it has engaged FronTier Flex, an investor relations (IR) and marketing group based in Toronto, Canada to provide Canadian IR and strategic marketing services.

    Sernova President and CEO Dr. Philip Toleikis commented, "FronTier’s engagement falls within the expanded communications strategy Sernova is implementing to help investors and shareholders stay well-informed as we advance our new US diabetes Phase I/II clinical study and other programs. FronTier’s media experience will increase Sernova’s visibility and reach into the investment community through strategic messaging and investor outreach.”

    Through their established network of financial industry professionals and marketing service providers, FronTier will assist the corporation by increasing market awareness for the corporation using a number of financial market communications initiatives, including facilitating in-person introductions for the corporation with institutional and retail brokers in Toronto and other financial capitals, and through media distribution on national television, radio and multiple online channels.

    Under the terms of the engagement, FronTier has been retained for a 12-month period for aggregate remuneration of $87,000 plus expenses.

    About Sernova Corp Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

    For further information contact:

    Dominic Gray, Corporate Communications Tel: (519) 858-5126 Dominic.Gray@sernova.com www.sernova.com

    Philip Toleikis, Ph.D., President and CEO Tel: (519) 858-5184 info@sernova.com www.sernova.com

    Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

    Forward-Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward- looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

    Back



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    September 28, 2018

    2018 Financial Report - 3rd Quarter

    July 31, 2018

    September 28, 2018

    2018 Management Discussion & Analysis (MD&A) - 3rd Quarter

    July 31, 2018

    July 18, 2018

    2018 Financial Report - 2nd Quarter

    June 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 2nd Quarter

    May 28, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News